Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies

Despite remarkable advances in the treatment of multiple myeloma (MM) in the last decades, the prognosis of patients harboring highrisk cytogenetic abnormalities remains dismal as compared to that of standard-risk patients. Proteasome inhibitors have been demonstrated to partially ameliorate the pro...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haematologica
Main Authors: Mina, Roberto, Bonello, Francesca, Petrucci, Maria Teresa, Liberati, Anna Marina, Conticello, Concetta, Ballanti, Stelvio, Musto, Pellegrino, Olivieri, Attilio, Benevolo, Giulia, Capra, Andrea, Gilestro, Milena, Galieni, Piero, Cavo, Michele, Siniscalchi, Agostina, Palumbo, Antonio, Montefusco, Vittorio, Gaidano, Gianluca, Omedé, Paola, Boccadoro, Mario, Bringhen, Sara
Formato: Artigo
Idioma:Inglês
Publicado em: Fondazione Ferrata Storti 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8018137/
https://ncbi.nlm.nih.gov/pubmed/32107329
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2019.243428
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados